A study by researchers at Mass General Brigham hospital in Boston found that one in five COVID-infected individuals treated with antiviral medication Paxlovid experienced viral rebound, shedding live and potentially contagious virus after an initial negative test. The rebound phenomenon was more common than expected, occurring over 20% of the time with Paxlovid. The study highlights the need for patient counseling and re-testing during Paxlovid treatment, despite its effectiveness in reducing hospitalization and death in severe COVID-19 cases.
A man with HIV who underwent a stem cell transplant to treat blood cancer has been in remission for nearly two years, joining five others who are cured or possibly cured.
Enanta Pharma (ENTA) to Present New Data for EDP-235 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL
WATERTOWN, Mass. (BUSINESS WIRE) Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease inhibitor in development as an oral, once-daily treatment for COVID-19, w.